Status:
RECRUITING
Protective Effect of Thymosin Α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II)
Lead Sponsor:
Nanjing Medical University
Collaborating Sponsors:
Beijing Anzhen Hospital
Second Affiliated Hospital of Nanchang University
Conditions:
Acute Aortic Syndrome
Aortic Dissection Type a
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
Systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS) are the major causes of death in patients with acute aortic syndrome (AAS). Therefore, the prevention of S...
Eligibility Criteria
Inclusion
- The patients are conformed to 2010 ACC/AHA guidelines for the diagnosis and treatment of thoracic aortic disease (TAD) within two weeks of onset;
- Patients with acute aortic syndrome confirmed clinically and radiologically and planning to undergo emergency surgery were enrolled.
- The patients' age between 18 \~90 years old.
- Agree to participate in the study and sign the informed consent.
Exclusion
- Patients allergic to Thymosin α1;
- Lactating women and pregnant women;
- Patients with mental diseases, drug and alcohol dependence;
- Refuse to participate in this study and refuse to sign the informed consent.
Key Trial Info
Start Date :
July 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
330 Patients enrolled
Trial Details
Trial ID
NCT05339529
Start Date
July 1 2022
End Date
December 31 2025
Last Update
December 12 2024
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China
2
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
3
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China, 210029
4
Nanjing First Hospital Nanjing Medical University
Nanjing, Jiangsu, China